Inmunoterapia y oncología
El tratamiento del cáncer ha pasado de envenenar las células que se dividen a dirigir el sistema inmunitario hacia el tumor y a usar fármacos que llevan su carga terapéutica únicamente al tejido canceroso. Esta área concentra más gasto en desarrollo de medicamentos que cualquier otra.
388 acciones
| # | Nombre |
Fondos con posición | Crecimiento | Crecimiento % |
Valor del fondo |
|
|---|---|---|---|---|---|---|
| 1 |
1
Johnson & Johnson
JNJ
USD 624 mil M
| 4,703 | +40 | +0.9% | USD 457 mil M |
|
| 2 |
2
AbbVie
ABBV
USD 513 mil M
| 4,240 | +121 | +3% | USD 335 mil M |
|
| 3 |
3
Merck
MRK
USD 365 mil M
| 3,857 | +44 | +1% | USD 254 mil M |
|
| 4 |
4
Amgen
AMGN
USD 236 mil M
| 3,168 | +14 | +0.4% | USD 162 mil M |
|
| 5 |
5
Pfizer
PFE
USD 172 mil M
| 2,845 | -121 | -4% | USD 91.9 mil M |
|
| 6 |
6
Bristol-Myers Squibb
BMY
USD 126 mil M
| 2,533 | -13 | -0.5% | USD 96.7 mil M |
|
| 7 |
7
Gilead Sciences
GILD
USD 193 mil M
| 2,294 | -39 | -2% | USD 141 mil M |
|
| 8 |
8
Novartis
NVS
USD 292 mil M
| 1,626 | +21 | +1% | USD 21.3 mil M |
|
| 9 |
9
AstraZeneca
AZN
USD 262 mil M
| 1,509 | +123 | +9% | USD 196 mil M |
|
| 10 |
10
Regeneron Pharmaceuticals
REGN
USD 82.1 mil M
| 1,341 | -60 | -4% | USD 57.1 mil M |
|
| 11 |
11
GSK
GSK
USD 100 mil M
| 1,046 | +7 | +0.7% | USD 18.2 mil M |
|
| 12 |
12
Incyte
INCY
USD 23.6 mil M
| 862 | +46 | +6% | USD 23 mil M |
|
| 13 |
13
Natera
NTRA
USD 58.8 mil M
| 851 | +83 | +11% | USD 37.2 mil M |
|
| 14 |
14
Exelixis
EXEL
USD 15.8 mil M
| 761 | +59 | +8% | USD 14.1 mil M |
|
| 15 |
15
Revolution Medicines
RVMD
USD 41.8 mil M
| 696 | +181 | +35% | USD 40.1 mil M |
|
| 16 |
16
Halozyme
HALO
USD 14.1 mil M
| 675 | +37 | +6% | USD 9618 M |
|
| 17 |
17
Jazz Pharmaceuticals
JAZZ
USD 13.8 mil M
| 649 | +71 | +12% | USD 15.5 mil M |
|
| 18 |
18
Guardant Health
GH
USD 21.6 mil M
| 601 | +115 | +24% | USD 20 mil M |
|
| 19 |
19
Tempus AI
TEM
USD 12.4 mil M
| 489 | +61 | +14% | USD 6406 M |
|
| 20 |
20
Lantheus
LNTH
USD 6543 M
| 468 | +60 | +15% | USD 8342 M |
|
| 21 |
21
ImmunityBio
IBRX
USD 9411 M
| 405 | +19 | +5% | USD 1775 M |
|
| 22 |
22
Takeda Pharmaceutical
TAK
USD 64.1 mil M
| 380 | +17 | +5% | USD 1671 M |
|
| 23 |
23
Veracyte
VCYT
USD 3605 M
| 370 | +36 | +11% | USD 5230 M |
|
| 24 |
24
Recursion Pharmaceuticals
RXRX
USD 1941 M
| 344 | +9 | +3% | USD 1328 M |
|
| 25 |
25
Qiagen
QGEN
USD 10.2 mil M
| 338 | -9 | -3% | USD 5685 M |
|